Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen

Lorenzo Guglielmetti; Wladimir Sougakoff; Thomas Maitre; Florence Brossier; Vincent Jarlier; Jérôme Robert; Nicolas Veziris; Alexandra Aubry; French National Reference Center of Mycobacteria

doi:10.1093/cid/ciy808

Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen

Clin Infect Dis. 2019 Apr 8;68(8):1410-1411. doi: 10.1093/cid/ciy808.

Authors

Lorenzo Guglielmetti^{1

2}, Wladimir Sougakoff^{1

2}, Thomas Maitre^{1

2}, Florence Brossier^{1

2}, Vincent Jarlier^{1

2}, Jérôme Robert^{1

2}, Nicolas Veziris^{2

3}, Alexandra Aubry^{1

2}; French National Reference Center of Mycobacteria

Affiliations

¹ APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix.
² Sorbonne Université, Medecine, Unité 1135, Centre d'immunologie et des Maladies Infectieuses Team E13, CR7 INSERM.
³ APHP, CNR-MyRMA, Département de Bactériologie, Hôpitaux Universitaires de l'Est Parisien, Paris, France.

PMID: 30239638
DOI: 10.1093/cid/ciy808

Abstract

The World Health Organization recommends shortcourse regimen (SCR) to treat multidrug resistant tuberculosis for patients with strains susceptible by line-probe assays (LPAs) to second-line drugs. Our retrospective study shows LPAs have suboptimal specificity in predicting eligibility for SCR; a quarter of eligible patients would receive inadequate therapy with SCR.

Keywords: WHO; line probe assay; molecular testing; multidrug-resistance; tuberculosis.

MeSH terms

Adult
Antitubercular Agents / therapeutic use*
Humans
Microbial Sensitivity Tests / standards*
Molecular Typing / standards*
Mycobacterium tuberculosis / drug effects
Retrospective Studies
Tuberculosis, Multidrug-Resistant / diagnosis*
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / microbiology

Substances

Antitubercular Agents